LYLaurent Yon

Laurent Yon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laurent Yon has a total of 247 co-authors. Here are the top co-authors by number of shared publications:

  • Hubert Vaudry

    Institut National de la Santé et de la Recherche Médicale U413 (E.T., J.G., A.P., H.G., L.G., H.L., H.V., L.Y., Y.A.), Laboratory of Cellular and Molecular Neuroendocrinology, European Institute for Peptide Research (Institut Fédératif de Recherche Multidisciplinaires sur les Peptides 23), University of Rouen, 76821 Mont-Saint-Aignan, France

    25 shared publications
  • Youssef Anouar

    Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie Univ, UNIROUEN, INSERM, Rouen, France

    23 shared publications
  • Maité Montero-Hadjadje

    Univ. Rouen-Normandie, Normandie Université, INSERM, U1239, Laboratoire Différenciation et Communication Neuroendocrine, Endocrine et Germinale (NorDiC), Institut de Recherche et d’Innovation Biomédicale de Normandie, Rouen, France

    21 shared publications
  • Johann Guillemot

    CIRI, Centre International de Recherche en Infectiologie, GIMAP team, Université de Lyon, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Lyon, France

    19 shared publications
  • Alain Fournier

    INRS-Institut Armand Frappier, University of Quebec, Pointe-Claire, PQ, Canada H9R1G6

    14 shared publications
  • H. Vaudry

    Europ. Inst. Pept. Res. (IFRMP 23), Lab. Cell. Mol. Neuroendocrinol., INSERM U413, Univ. Rouen, France

    13 shared publications

Latest Publications

  • Open Access

    Characterization of the EM66 Biomarker in the Pituitary and Plasma of Healthy Subjects With Different Gonadotroph Status and Patients With Gonadotroph Tumor

    by Johann Guillemot, Marlène Guérin, Anne-Françoise Cailleux, Antoine-Guy Lopez, Jean-Marc Kuhn, Youssef Anouar, Laurent Yon

    Granins and their derived-peptides are useful markers of secretion from normal and tumoral neuroendocrine cells. The need to identify new diagnostic markers for neuroendocrine tumors, including pituitary tumors prompted us to determine plasma levels of the secretogranin II-derived peptide EM66 in healthy volunteers with different gonadotroph status and to evaluate its usefulness as a circulating marker for the diagnosis of gonadotroph tumor. Using a radioimmunoassay, we determined plasma EM66 concentrations in healthy men and women volunteers in different physiological conditions in relation with the gonadotroph function. Our results revealed that in men, in women with or without contraception, in pregnant or post-menopausal women, plasma EM66 concentrations are not significantly different, and did not show any correlation with gonadotropin levels. In addition, stimulation or inhibition tests of the gonadotroph axis had no effect on EM66 levels, whatever the group of healthy volunteers investigated while gonadotropin levels showed the expected variations. Immunohistochemical experiments and HPLC analysis showed the occurrence of EM66 in pituitary gonadotroph, lactotroph and corticotroph tumors but not in somatotroph tumor. In patients with gonadotroph or lactotroph tumor, plasma EM66 levels were 1.48 (0.82–4.38) ng/ml and 2.49 (1.19–3.54) ng/ml, respectively. While median value of EM66 was significantly lower in patients with gonadotroph tumor compared to healthy volunteers [2.59 (0.62–4.95) ng/ml], plasma EM66 concentrations were in the same range as normal values and did not show any correlation with gonadotropin levels. These results show that plasma EM66 levels are independent of the activity of the gonadotroph axis in healthy volunteers and, while EM66 levels are reduced in gonadotroph tumors, plasma EM66 does not provide a helpful marker for the diagnosis of these tumors.

  • Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model

    by M. Denorme, L. Yon, C. Roux, B.J. Gonzalez, E. Baudin, Y. Anouar, C. Dubessy


  • Open Access

    Characterization and Plasma Measurement of the WE-14 Peptide in Patients with Pheochromocytoma

    by Johann Guillemot, Marlène Guérin, Erwan Thouënnon, Maité Montéro-Hadjadje, Jérôme Leprince, Hervé Lefebvre, Marc Klein, Mihaela Muresan, Youssef Anouar, Laurent Yon

    Granins and their derived peptides are valuable circulating biological markers of neuroendocrine tumors. The aim of the present study was to investigate the tumoral chromogranin A (CgA)-derived peptide WE-14 and the potential advantage to combine plasma WE-14 detection with the EM66 assay and the existing current CgA assay for the diagnosis of pheochromocytoma. Compared to healthy volunteers, plasma WE-14 levels were 5.4-fold higher in patients with pheochromocytoma, but returned to normal values after surgical resection of the tumor. Determination of plasma CgA and EM66 concentrations in the same group of patients revealed that the test assays for these markers had an overall 84% diagnostic sensitivity, which is identical to that determined for WE-14. However, we found that WE-14 measurement improved the diagnostic sensitivity when combined with the results of CgA or EM66 assays. By combining the results of the three assays, the sensitivity for the diagnosis of pheochromocytoma was increased to 95%. In fact, the combination of WE-14 with either CgA or EM66 test assays achieved 100% sensitivity for the diagnosis of paragangliomas and sporadic or malignant pheochromocytomas if taken separately to account for the heterogeneity of the tumor. These data indicate that WE-14 is produced in pheochromocytoma and secreted into the general circulation, and that elevated plasma WE-14 levels are correlated with the occurrence of this chromaffin cell tumor. In addition, in association with other biological markers, such as CgA and/or EM66, WE-14 measurement systematically improves the diagnostic sensitivity for pheochromocytoma. These findings support the notion that granin-processing products may represent complementary tools for the diagnosis of neuroendocrine tumors.


  • Normotensive Incidentally Discovered Pheochromocytomas Display Specific Biochemical, Cellular, and Molecular Characteristics

    by Magalie Haissaguerre, Maïté Courel, Philippe Caron, Sophie Denost, Christophe Dubessy, Philippe Gosse, Vincent Appavoupoulle, Geneviève Belleannée, Marie-Laure Jullié, Maité Montero-Hadjadje, et al.

    A number of incidentally discovered pheochromocytomas are not associated with hypertension. The characteristics of normotensive incidentally discovered pheochromocytomas (NIPs) are poorly known. The purpose of this work was to assess the clinical, hormonal, histological, and molecular features of NIPs. This was a retrospective cohort recruited from 2001 to 2011 in 2 tertiary care medical departments. Clinical, biological, and radiological investigations performed in 96 consecutive patients with sporadic unilateral pheochromocytomas were examined; 47 patients had overt pheochromocytomas responsible for hypertension. Among the patients with incidental pheochromocytomas, 28 had hypertension and 21 were normotensive (NIPs). A total of 62 tumors were examined to determine the Pheochromocytoma of the Adrenal Gland Scale Score, and 29 were studied for the expression of 16 genes involved in chromaffin cell function. Tumor size and metaiodobenzylguanidine (MIBG) scintigraphy results were similar for hypertensive pheochromocytomas (HPs) and NIPs. Patients with NIPs displayed reduced summed levels of urinary catecholamines and metanephrines and, more specifically, reduced levels of adrenaline and metadrenaline compared with those of patients with HPs (P < .001). Urinary metanephrines had 98% diagnostic sensitivity in patients with HPs and only 75% in patients with NIPs (P < .01). Tumor diameter positively correlated with the total amount of urinary concentrations of metanephrines in patients with HPs (P < .001) but not in patients with NIPs. NIPs displayed global decreased chromaffin gene expression (reaching significance for 5 of them) and 2 corresponding proteins (phenylethanolamine N-methyltransferase and secretogranin II) and a significant increase in the cellularity, mitotic activity, and presence of atypical mitosis (P < .05). NIPs differ from pheochromocytomas responsible for hypertension and display features of altered chromaffin differentiation. These tumors may be misdiagnosed with the use of the usual biological diagnostic tools.


  • Clinical, biochemical, genetic and histological features of composite pheochromocytoma/ganglioneuroma adrenal tumors: a series of seven cases from two French academic centres

    by Alice Bertron, Francoise Gobet, Estelle Louiset, Milene Tetsi-Nomigni, Luca Grumolato, Emmanuelle Leteurtre, Philippe Grise, Laurent Yon, Jean-Louis Wemeau, Herve Lefebvre

    Introduction: Adrenal pheochromocytomas have the same embryonic origin, i.e. the neural crest, as peripheral neuroblastic tumors such as ganglioneuromas, ganglioneuroblastomas and neuroblastomas. Ganglioneuromas are benign and silent tumors in that they usually do not secrete catecholamines in contrast to pheochromocytomas. Rarely, they can associate with pheochromocytomas to form composite tumors. Patients and methods: We have retrospectively studied seven patients with pheochromocytoma/ganglioneuroma composite adrenal tumor followed up in two French academic departments of endocrinology. The clinical, biochemical, genetic and histological characteristics of the tumors were collected. In addition, immunohistochemical labelling of tumor slices with specific antibodies directed against the key enzyme for adrenaline synthesis phenylethanolamine N-methyltransferase (PNMT) were carried out in order to better individualize the two components of the neoplasms. Results: In all cases, association of the adrenal mass with clinical and biological signs of catecholamine excess led to the initial diagnosis of pheochromocytoma followed by adrenal surgery. The ganglioneuroma components of the neoplasms were identified at pathological examination of the tissues. Four patients carried germinal mutations affecting the NF1 (two patients), KIF1Bbeta (one patient) and MYC-associated factor (MAX; one patient) genes. Five patients harboured associated neoplasias and two patients had subclinical hypercortisolism related to hyperplasia of the adrenal cortex adjacent to the tumors. Immunohistochemical PNMT labellings of tumor sections allowed perfect discrimination of the two tumor tissue components by revealing intense staining of pheochromocytes contrasting with no signal in ganglion cells. Conclusion: We report a large series of adult adrenal pheochromocytoma/ganglioneuroma composite tumors. In addition, we show that, in addition to routine histological examination of the tumor tissues, immunohistochemical studies with antibodies to PNMT can be helpful for the diagnosis of the disease by facilitating identification of the two tumor components.

  • The neuropeptide 26RFa is expressed in human prostate cancer and stimulates the neuroendocrine differentiation and the migration of androgeno-independent prostate cancer cells

    by Jessy Alonzeau, David Alexandre, Lydie Jeandel, Maïté Courel, Coralie Hautot, Fatima-Zohra El Yamani, Françoise Gobet, Jérôme Leprince, Rabia Magoul, Afaf Amarti, et al.


  • Open Access

    Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66

    by J Guillemot, E Thouënnon, M Guérin, V Vallet-Erdtmann, A Ravni, M Montéro-Hadjadje, H Lefebvre, M Klein, M Muresan, N G Seidah, et al.

    We have previously demonstrated that measurement of tissue concentrations of the secretogranin II (SgII or SCG2 as listed in the HUGO database)-derived peptide EM66 may help to discriminate between benign and malignant pheochromocytomas and that EM66 represents a sensitive plasma marker of pheochromocytomas. Here, we investigated the gene expression and protein production of SgII in 13 normal adrenal glands, and 35 benign and 16 malignant pheochromocytomas with the goal to examine the molecular mechanisms leading to the marked variations in the expression of EM66 in tumoral chromaffin tissue. EM66 peptide levels were 16-fold higher in benign than in malignant pheochromocytomas and had an area under the receiver-operating characteristic curve of 0.95 for the distinction of benign and malignant tumors. Q-PCR experiments indicated that the SgII gene was significantly underexpressed in malignant tumors compared with benign tumors. Western blot analysis using antisera directed against SgII and SgII-derived fragments revealed lower SgII protein and SgII-processing products in malignant tumors. Western blot also showed that low p-cAMP-responsive element-binding (CREB) concentrations seemed to be associated with the malignant status. In addition, the prohormone convertase PC1 and PC2 genes and proteins were overexpressed in benign pheochromocytomas compared with malignant pheochromocytomas. Low concentrations of EM66 found in malignant tumors are associated with reduced expression and production of SgII and SgII-derived peptides that could be ascribed to a decrease in SgII gene transcription, probably linked to p-CREB down-regulation, and to lower PC levels. These findings highlight the mechanisms leading to lower concentrations of EM66 in malignant pheochromocytoma and strengthen the notion that this peptide is a suitable marker of this neuroendocrine tumor.


  • Expression of Trophic Peptides and Their Receptors in Chromaffin Cells and Pheochromocytoma

    by Erwan Thouёnnon, Alice Pierre, Laurent Yon, Youssef Anouar

    Pheochromocytomas are catecholamine-producing tumors arising from chromaffin cells of the adrenal medulla or extra-adrenal location. Along with catecholamines, tumoral cells produce and secrete elevated quantities of trophic peptides which are normally released in a regulated manner by the normal adrenal medulla. Among these peptides, the amounts of pituitary adenylate cyclase-activating polypeptide (PACAP), adrenomedullin (AM), and neuropeptide Y (NPY) are particularly high. These peptides can exert endocrine, paracrine or autocrine effects in numerous cell types. In particular, they have been shown to be involved in cell proliferation and survival, catecholamine production and secretion, and angiogenesis. Some of these processes are exacerbated in pheochromocytomas, raising the possibility of the involvement of trophic peptides. Here, we review the expression levels of NPY, PACAP, and AM and theirs receptors in chromaffin cells and pheochromocytomas, and address their possible implication in the adrenal medulla tumorigenesis and malignant development of pheochromocytomas.